NovelStem Increases NewStem Ownership to 27.3% Following Achievement of Development Milestones for Stem-Cell-Based Cancer Treatments Resistance Diagnostic
The original release is unavailable here.
Earlier from Novelstem International
- NovelStem Provides Shareholder Update
- Hollywood Media Changes Name and Stock Symbol to NovelStem International Corp. and “NSTM” to Reflect Focus on Stem Cell-Based Diagnostics to Better Select Cancer Chemotherapies
- NewStem Announces $4 million Seed Investment
- Hollywood Media Completes Transformational Investment in NewStem, Israel-Based Developer of Haploid Stem Cell-Based Diagnostics to Predict Chemotherapy Resistance